Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS Platform Trial with eIF2B Agonist DNL343

Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS Platform Trial with eIF2B Agonist DNL343

  • Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks.
  • Overall, DNL343 was found to be safe and well-tolerated.
  • Additional analyses, including neurofilament light (NfL) and other fluid biomarkers, pre-specified sub-group analyses and analyses from the active treatment extension period are expected later in 2025.
Neals logo